Company: BLTE
Filing Date: 2025-12-02
Form Type: 424B5
Source: 0001104659-25-117702
Chunk: 38

Company: BELITE BIO, INC
Filing Date: 2025-12-02
Form: 424B5
Chunk 38
---
 their tax advisors regarding our PFIC status for any taxable year and the potential application of the PFIC rules to an investment in our ADSs or ordinary shares including the availability and the advisability of making a QEF Election or a mark-to-market election with respect to us, and the application of the PFIC rules to any of our subsidiaries. See “Material Tax Considerations—United States Federal Income Tax Considerations—Passive Foreign Investment Company” for further information.

<div align='center'>S-23</div>

TABLE OF CONTENTS

### USE OF PROCEEDS
We estimate that we will receive proceeds of approximately US$328.2 million, or US$377.5 million if the underwriters exercise their option to purchase additional ADSs in full, based on the public offering price of US$154.00 per ADS and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us.

We intend to use the net proceeds from this offering under this prospectus supplement for (i) commercialization preparation, including building our in-house commercialization team, establishing sales network and systems, and preparing for the commercial manufacture of our future products, if approved, (ii) development and expansion of pipelines, and (iii) working capital and other general corporate purposes.

The amounts and timing of our actual expenditures will depend upon numerous factors, including the progress of our development and commercialization efforts, the status of and results from our clinical, non-clinical or pre-clinical trials, whether or not we enter into strategic collaborations or partnerships, and our operating costs and expenditures. Accordingly, our management will have significant flexibility in applying the net proceeds of this offering. In addition, while we have not entered into any outstanding binding agreements or commitments relating to any significant transaction as of the date of this prospectus supplement, we may use a portion of the net proceeds to pursue acquisitions, joint ventures, and other strategic transactions.

<div align='center'>S-24</div>

TABLE OF CONTENTS

CAPITALIZATION The following table sets forth our capitalization as of September 30, 2025: • on an actual basis; and • on an as adjusted basis to give effect to our issuance and sale of ADSs in this offering, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us in connection with this offering, assuming the underwriters do not exercise their option to purchase additional ADSs. The information set forth in the following table should be read in conjunction with and is qualified in its